Who owns BridgeBio Oncology Therapeutics, Inc. (BBOT)? Elite investor 13F holders
2 tracked elite investors reported holding BridgeBio Oncology Therapeutics, Inc as of 2026-06-30, including Alphabet, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | BRIDGEBIO ONCOLOGY THERAPEUT | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 21512220.00 USD | 2823126.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | BRIDGEBIO ONCOLOGY THERAPEUT | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 446532.00 USD | 58600.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.